GT Biopharma Overview
- Year Founded
-
1965
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
GTBP
- Investments
-
1
- Share Price
-
$2.91
- (As of Friday Closing)
GT Biopharma General Information
Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Contact Information
Website
www.gtbiopharma.comCorporate Office
- 505 Montgomery Street
- 10th Floor
- San Francisco, CA 94111
- United States
Corporate Office
- 505 Montgomery Street
- 10th Floor
- San Francisco, CA 94111
- United States
GT Biopharma Timeline
GT Biopharma Stock Performance
As of 20-Nov-2026, GT Biopharma’s stock price is $2.91. Its current market cap is $6.33M with 2.14M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.91 | $3.18 | $2.87 - $23.60 | $6.33M | 2.14M | 77.6K | $47.97 |
GT Biopharma Financials Summary
As of 30-Sep-2026, GT Biopharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,715 | 5,824 | 398 | (5,359) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (16,454) | (28,350) | (13,564) | (8,164) |
| Net Income | (16,590) | (28,354) | (13,162) | (7,597) |
| Total Assets | 10,568 | 8,106 | 4,232 | 14,109 |
| Total Debt | 0 | 11 | 0 | 58 |
GT Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GT Biopharma Comparisons
Industry
Financing
Details
GT Biopharma Competitors (88)
One of GT Biopharma’s 88 competitors is Alligator Bioscience, a Formerly VC-backed company based in Lund, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alligator Bioscience | Formerly VC-backed | Lund, Sweden | ||||
| Soligenix | Formerly VC-backed | Princeton, NJ | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA |
GT Biopharma Patents
GT Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022347132-A1 | B7-h3 targeting fusion proteins and methods of use thereof | Pending | 16-Sep-2021 | ||
| CA-3231445-A1 | B7-h3 targeting fusion proteins and methods of use thereof | Pending | 16-Sep-2021 | ||
| EP-4401776-A1 | B7-h3 targeting fusion proteins and methods of use thereof | Pending | 16-Sep-2021 | ||
| EP-4401776-A4 | B7-h3 targeting fusion proteins and methods of use thereof | Pending | 16-Sep-2021 | ||
| US-20250145715-A1 | B7-h3 targeting fusion proteins and methods of use thereof | Pending | 16-Sep-2021 | C07K16/2827 |
GT Biopharma Signals
GT Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GT Biopharma Acquisitions (1)
GT Biopharma’s most recent deal was a Merger/Acquisition with Oxis International. The deal was made on 05-Sep-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oxis International | 05-Sep-2017 | Merger/Acquisition | Pharmaceuticals |
GT Biopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.46 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
GT Biopharma FAQs
-
When was GT Biopharma founded?
GT Biopharma was founded in 1965.
-
Where is GT Biopharma headquartered?
GT Biopharma is headquartered in San Francisco, CA.
-
What is the size of GT Biopharma?
GT Biopharma has 9 total employees.
-
What industry is GT Biopharma in?
GT Biopharma’s primary industry is Drug Discovery.
-
Is GT Biopharma a private or public company?
GT Biopharma is a Public company.
-
What is GT Biopharma’s stock symbol?
The ticker symbol for GT Biopharma is GTBP.
-
What is the current stock price of GT Biopharma?
As of 20-Nov-2026 the stock price of GT Biopharma is $2.91.
-
What is the current market cap of GT Biopharma?
The current market capitalization of GT Biopharma is $6.33M.
-
Who are GT Biopharma’s competitors?
Alligator Bioscience, Soligenix, Blueprint Medicines, Ionis Pharmaceuticals, and Immune-Onc Therapeutics are some of the 88 competitors of GT Biopharma.
-
What is GT Biopharma’s annual earnings per share (EPS)?
GT Biopharma’s EPS for 12 months was $47.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process